You have done the research. You have read the Joe Tippens story. You have watched Mel Gibson’s Joe Rogan interview. Reddit threads, Telegram groups, the OneDayMD case files, and peer-reviewed papers that most cancer doctors have never opened — you have found all of it. Now you want to know one thing: what does the full protocol actually look like when someone puts all four drugs together?

This article is the answer.

Four generic drugs. All cheap. All decades old. All now at the centre of the most active cancer repurposing debate in modern medicine. This guide covers why each drug does a separate job, what the combined case record shows across hundreds of real patients in 2025 and 2026, how to dose each compound, what lab tests you need, and how American patients are legally sourcing all four right now.

---

Why Four Drugs Instead of One

Standard cancer treatment logic says: find the strongest single agent and push the highest dose possible. The repurposed drug protocol takes a different approach entirely. Cancer cells adapt fast. Push them with one pathway and they reroute around it. Push them with four separate, non-overlapping attacks at the same time and they have nowhere left to go.

Fenbendazole disrupts microtubule function and blocks glycolysis, while ivermectin targets cancer signalling pathways including STAT3 and Wnt/β-catenin. Together, the combination covers microtubule collapse, metabolic blocking, signalling shutdown, and immune changes.

A The Medical Advisordd mebendazole’s kinase blocking and anti-spread action. Then add HCQ’s autophagy shutdown and immune boost. The result is a four-way attack on cancer cells’ structure, energy supply, survival signals, and escape routes — all running together.

That is the core logic behind the full stack. Each section below explains what one drug brings and why removing it leaves a gap the other three cannot fill.

---

The Four Drugs and What Each One Does

Ivermectin: The Signalling Disruptor

Ivermectin was the first of the four to attract serious cancer attention. A 2015 Nobel Prize recognised its antiparasitic discovery. Over 100 peer-reviewed papers have since mapped its anticancer actions. In February 2026, KFF Health News reported that the National Cancer Institute confirmed it actively studies ivermectin’s ability to kill cancer cells.

Researchers document at least 15 separate ways ivermectin attacks cancer cells. The most important involve PAK1, STAT3, Wnt/β-catenin, and AKT/mTOR — the core growth and survival signals cancer cells depend on. Beyond those effects, ivermectin also reverses multidrug resistance. Consequently, cancer cells that have stopped responding to chemotherapy may respond again once ivermectin runs alongside it.

The Pancreatic Cancer Number That Changes the Conversation

A 54-year-old French man with Stage 4 pancreatic cancer saw his primary tumour shrink 93% and one liver lesion drop over 91% after just one month of adding ivermectin and mebendazole to his chemotherapy — compared to only 17% shrinkage over five prior chemotherapy cycles alone.

T The Medical Advisorhe chemo regimen had not changed. The doses had not changed. The only new variable was two repurposed drugs added alongside it. That gap — 17% versus 93% — is what chemotherapy boosting looks like in a real patient.

---

Fenbendazole: The Metabolic Weapon

Fenbendazole reached a mass audience through Joe Tippens — a stage-four lung cancer patient who achieved a full response in 2016 after adding fenbendazole and a supplement stack to an experimental trial. His story drove a 150% rise in global search interest in 2025, a peer-reviewed case series in the same year, and a worldwide patient community now numbering in the tens of thousands.

How Fenbendazole Hits Cancer Cells

Fenbendazole works through four main actions: microtubule collapse, GLUT transporter blocking to cut off glucose, p53 tumour suppressor activation, and proteasome disruption. Its key edge over other benzimidazoles, however, is glycolysis blocking — cutting off the backup energy route that drug-resistant cancer cells use when their main energy systems fail.

An 85-year-old Toronto man with a bile duct tumour that kept growing after radiation started ivermectin and fenbendazole at mild doses. After four months, his scan showed complete remission with no chemotherapy, no immunotherapy, and no further radiation.

• The Medical Advisor—

Mebendazole: The Brain Penetrator and Spread Blocker

Mebendazole carries the strongest clinical record of any benzimidazole in the stack. Doctors have used it in humans since 1971. Researchers have tested it in over 6,000 people across 39 clinical trials for parasitic disease, and in Phase I and Phase II human cancer trials at Johns Hopkins, eClinicalMedicine, and multiple European oncology centres.

Two properties make mebendazole essential here. First, it crosses the blood-brain barrier — giving it a reach inside brain tumours that no other drug in this group can match. Second, it actively blocks cancer spread by lowering ITGβ4 expression and cancer stem cell activity, fighting not just the main tumour but the cancer’s ability to take root in new sites.

The 12-Month Glioblastoma Shrinkage Story

A 69-year-old Kentucky man with a 4.5cm glioblastoma started ivermectin and mebendazole and later added fenbendazole. Over 12 months of MRI monitoring, his brain tumour consistently shrank — and his doctor told him to keep doing exactly what he was doing.

G The Medical Advisorlioblastoma almost always comes back. Consistent shrinkage over a full year from a generic drug protocol is not something standard oncology can routinely offer. Furthermore, this result was one of 119 documented brain cancer cases in the mebendazole and ivermectin case database as of March 2026.

---

HCQ: The Autophagy Trap

Hydroxychloroquine completes the stack by closing the cancer cell’s last exit. When ivermectin, fenbendazole, and mebendazole place cancer cells under combined stress, those cells try to switch on autophagy — a self-digestion process that generates emergency fuel and clears damaged proteins. HCQ stops that process directly by blocking autophagosomes from joining lysosomes inside the cell.

HCQ’s Immune Bonus

Beyond autophagy blocking, HCQ raises MHC-I protein levels on tumour cell surfaces — making cancer cells visible again to the body’s immune system after tumours have deliberately hidden themselves. A 2025 American Association for Cancer Research abstract confirmed this immune effect across melanoma, non-small cell lung cancer, ovarian cancer, and glioblastoma cell lines.

Together, the four drugs create a closed loop. Ivermectin pushes cancer cells into stress. Fenbendazole then cuts the metabolic escape route. Mebendazole blocks cell division and spread to new sites. Finally, HCQ shuts down autophagy — the last available survival move. As a result, the cancer cell has no working exit.

---

The Peer-Reviewed Protocol Behind This Stack

Drs. Baghli, Martinez, and Marik published a peer-reviewed protocol covering ivermectin, fenbendazole, and mebendazole together in September 2024 in the Journal of Orthomolecular Medicine. That publication marked the first time a triple-antiparasitic cancer protocol appeared in peer-reviewed oncology literature.

A February 2026 review examined the triple combination using a structured PRISMA framework and found five cases with clear links between the protocol and tumour shrinkage or falling markers — including a Stage IV breast cancer patient whose liver spread resolved, a pancreatic cancer patient whose CT looked normal at 11 months, and an endometrial cancer patient whose spread shrank roughly 60% over two months.

A The Medical Advisordding HCQ to this published triple protocol is the logical next step — and the full combination this guide covers.

---

The 590-Case Report Record: What the Data Shows

As of March 2026, a running case report record using ivermectin, fenbendazole, and mebendazole — alone and together — has reached 590 documented cases across multiple cancer types.

R The Medical Advisoresearchers have not run controlled trials on these cases. Many involve concurrent chemotherapy or immunotherapy that makes it impossible to fully separate the drug effects. That limit is real and worth stating clearly. However, case reports can legitimately show a consistent pattern. Consequently, 590 cases across diverse cancer types, countries, and treatment histories — all showing repeated links between starting these drugs and tumour shrinkage or falling biomarkers — form a pattern worth taking seriously.

Lung Cancer Results

The lung cancer record is the largest single-type database for this stack, covering 41 cases as of February 2026. A 52-year-old Illinois man with Stage 4 non-small cell lung cancer spread to bones and brain started the triple protocol in December 2025. Within two months, his CEA tumour marker dropped from 719 to 18, and scans showed tumours shrinking or gone at multiple sites.

The Medical Advisor## Prostate Cancer Results

An 80-year-old Saudi Arabian man with Stage 4 prostate cancer spread to bone started ivermectin and mebendazole in September 2025, then added fenbendazole. Over four months, his PSA fell from 1,277 to 8.69 — a result his local doctor called a remarkable clinical response.

The Medical Advisor## Triple-Negative Breast Cancer Results

A 53-year-old Georgia woman with triple-negative breast cancer — a 2.5cm tumour, aggressive and poorly formed — started ivermectin, mebendazole, and fenbendazole alongside chemotherapy in September 2025. Four months later, both her breast surgeon and oncologist called the MRI findings “absolutely fantastic.”

T The Medical Advisorriple-negative breast cancer offers fewer targeted therapy options than most subtypes. Partly for that reason, TNBC patients appear more often in the early case report literature for this stack than their overall share of breast cancers would suggest.

Colorectal Cancer Results

An 82-year-old Tennessee man with Stage 4 rectal cancer received a six-month prognosis from his oncologist in February 2025. He started ivermectin and mebendazole. Six months later, doctors found him cancer-free.

• The Medical Advisor

Full Protocol Dosing (2026)

The dosing below reflects the published Baghli-Martinez-Marik protocol, community practice drawn from the 590-case database, and integrative medicine guidance. Always work with a qualified doctor before starting any off-label protocol.

Ivermectin Dosing

Take 12mg to 24mg daily — or 1mg per kilogram of body weight — on a three-days-on, four-days-off cycle. Take on an empty stomach with a full glass of water. For brain cancers or highly aggressive disease, some doctors use 2mg per kilogram daily within the same cycling structure, based on documented brain cancer case dosing. Higher doses require direct doctor oversight and regular liver monitoring.

Fenbendazole Dosing

Take 222mg to 444mg daily on a three-days-on, four-days-off cycle, with or after a fatty meal. For active aggressive cancer, community protocols typically use 500mg or more daily. Always take alongside CBD oil at 25mg sublingually and curcumin at 600mg twice daily — both improve fenbendazole absorption and add extra anticancer activity. Vitamin E succinate at 400IU daily completes the original Tippens absorption stack.

Mebendazole Dosing

Start at 500mg daily with a high-fat meal. Adjust upward based on doctor guidance and liver enzyme results. For brain cancers or metastatic disease, published case reports show doctors using 1,000mg to 1,500mg daily. Practitioners can apply the same three-days-on, four-days-off cycle used for other benzimidazoles, though many run mebendazole daily given its strong long-term human safety record at standard doses.

HCQ Dosing

Start at 200mg daily and apply the hard ceiling of 5mg per kilogram of body weight — a 70kg patient’s daily ceiling is 350mg. Take separately from antacids by at least four hours. Before starting, get a baseline ECG because of HCQ’s effect on the QT interval. Additionally, schedule a baseline eye exam before long-term use, with annual check-ups thereafter.

---

Supporting Compounds That Strengthen the Stack

The drugs alone do not make the complete protocol. Supporting supplements play proven roles in lifting absorption, adding extra actions, and protecting the liver under the load of multiple compounds running together.

CBD Oil (25mg sublingual daily) raises the absorption of both fenbendazole and HCQ. Beyond absorption, it also adds its own documented anticancer and anti-inflammatory activity. For these reasons, CBD oil has been part of the original Tippens stack from the start.

Bioavailable Curcumin (600mg twice daily) activates p53, lowers NF-κB inflammation, makes cancer cells more sensitive to drug effects, and works alongside all four primary compounds. Use a phospholipid-complexed or nanoparticle form to get real absorption.

Vitamin E Succinate (400IU daily) improves fenbendazole absorption and brings its own preclinical anticancer activity across multiple cancer types.

Berberine (500mg twice daily) blocks AMPK and mTOR, adds metabolic pressure on cancer cells, and may strengthen fenbendazole’s glycolysis-blocking effect. Doctors therefore include it increasingly in advanced protocol versions.

Milk Thistle / Silymarin (250mg twice daily) protects liver function while four compounds that all process through hepatic pathways run at the same time. Skipping this when running the full stack is not advisable.

---

Monitoring: What to Test and When

Running four drugs together means running a structured monitoring plan. That plan is what separates a safe, lasting protocol from an untracked risk.

Comprehensive Metabolic Panel Every Two to Four Weeks

Watch ALT and AST liver enzyme levels closely. All four primary drugs process through the liver to some extent. Elevated enzymes are the most common adverse signal doctors see across all compounds in this stack. Catching a rise early lets you adjust doses before any change becomes a clinical issue. Notably, all enzyme rises in published clinical trial data reversed when doctors reduced doses or briefly stopped the drug.

Baseline ECG Before Starting HCQ

Both HCQ and some chemotherapy agents prolong the QT interval. A baseline ECG establishes your personal QTc reading and identifies anyone for whom HCQ carries added cardiac risk. If you take digoxin, antidepressants, or antifungals, review those interactions with your doctor before adding HCQ to the stack.

Baseline Eye Exam and Annual Check-Ups

Retinopathy is HCQ’s main long-term risk — and fortunately, regular screening catches it early. Get a baseline exam before you start and book annual check-ups for any use beyond six months. Report blurring, colour changes, or reading problems to your doctor straight away.

Tumour Markers and Imaging on Schedule

Track your cancer-specific marker — CEA, CA19-9, PSA, CA15-3, or equivalent — at regular intervals. These give an objective measure of whether the protocol produces a response. Set your imaging schedule in direct coordination with your oncologist so results are read in the right clinical context.

---

Why the Combination Outperforms Any Single Drug

The clearest evidence that this is not four random drugs stacked together comes from patients who moved from a partial protocol to the full combination and saw a clear shift.

The Chemotherapy Comparison That Speaks for Itself

The French pancreatic cancer case makes this point directly. Five cycles of FOLFIRINOX produced just 17% tumour shrinkage. Adding ivermectin and mebendazole over the next five cycles drove a 93% volume drop in the primary pancreatic tumour and a 91% reduction in one liver lesion. The Medical Advisor Doctors changed nothing else. The repurposed drugs were the only new variable.

The Safety Picture Across 457 Cases

The combination also holds up on safety. Analysis of 457 case reports found minimal severe adverse effects even at high combined doses — only mild, brief symptoms such as nausea in a small share of patients. Pooled data from 36 cancer patients on ivermectin confirmed full tolerance at standard antiparasitic doses.

The Medical Advisor In short, the combination appears not only more effective than any drug used alone — it also appears safer than many standard oncology agents at normal dosing levels across hundreds of real-world cases.

---

Talking to Your Oncologist About This Protocol

Most oncologists in the USA will not bring up this protocol first. The reasons are structural rather than purely scientific. Licensing risk, guideline liability, and the memory of the COVID-19 controversy around both HCQ and ivermectin all play a role — even though neither controversy has any bearing on their cancer biology.

Three Approaches That Work

Understanding this dynamic in advance helps you navigate the conversation more effectively. First, bring peer-reviewed literature to the appointment. The Baghli-Martinez-Marik protocol from the Journal of Orthomolecular Medicine and the Johns Hopkins mebendazole Phase I trial are the two strongest starting points. Peer-reviewed data shifts the frame from patient anecdote to published evidence.

Ask About Interactions, Not Approval

Second, ask specifically about drug interactions rather than seeking endorsement. The practical question — “do any of these compounds interact with my current treatment in a way that creates risk?” — is a clinical safety question your oncologist can answer directly. It is a more productive entry point than asking for approval of off-label prescribing.

Finding an Integrative Physician

Third, if your oncologist will not engage at all, integrative oncology services at major cancer centres are growing fast. Functional and integrative medicine telehealth doctors can prescribe HCQ and ivermectin off-label where clinically appropriate, and they can provide the medical oversight that makes this protocol both safer and legally sound.

---

Legal Sourcing for All Four Drugs in the USA

Ivermectin 12mg and 24mg

Tennessee, Arkansas, Idaho, and Louisiana now sell ivermectin over the counter without a prescription. Residents of all other states can get it through a telehealth visit and a prescription filled by a licensed online pharmacy — typically under 24 hours from consultation to shipping. Always buy pharmaceutical-grade tablets. Never use veterinary ivermectin paste regardless of what dosing guides you find online.

Fenbendazole 222mg and 444mg

Fenbendazole remains a veterinary product in the USA, so no standard human prescription exists for it. Licensed international online pharmacies sell pharmaceutical-grade fenbendazole capsules for human use. Always request a third-party certificate of analysis confirming purity before you buy. Independent testing in 2024 found Amazon fenbendazole products averaging just 56% purity — meaning buyers got roughly half their stated dose.

Mebendazole 500mg

Doctors can prescribe mebendazole in all 50 states because it carries FDA approval as a human medicine. Integrative medicine telehealth platforms can write an off-label prescription where a physician judges it clinically appropriate. Because doctors and pharmacies have dispensed it as a generic for decades, costs stay low — often under $2 per tablet at standard doses.

HCQ 200mg and 400mg

Telehealth physicians with integrative and functional medicine training can prescribe HCQ off-label in all 50 states where clinically appropriate. Generic HCQ production is widespread, keeping costs accessible. Verify your pharmacy holds NABP accreditation before ordering at nabp.pharmacy.

---

Which Cancer Types Show the Strongest Evidence

The protocol carries case report evidence across nearly every major cancer category. However, the following tumour types currently show the most consistent documented response signals.

Lung cancer holds the largest single-type case database — 41 documented cases as of February 2026, covering both small-cell and non-small cell subtypes. Ivermectin and fenbendazole appear in most lung cancer cases, with mebendazole added specifically when doctors identify brain metastases.

Colorectal cancer has the strongest randomised trial data for mebendazole specifically. The full stack adds ivermectin’s chemotherapy-boosting action and fenbendazole’s p53 activation on top of mebendazole’s existing human trial record.

Prostate cancer shows consistent PSA drops across dozens of reported cases. The stack appears especially useful at managing bone metastases and at keeping remission after surgery in cases with positive margins or lymph node involvement.

Triple-negative breast cancer appears more often in the TNBC case subset than its share of all breast cancers would predict — likely because this subtype has the fewest targeted therapy options. The ASCO 2025 Cedars-Sinai Phase I/II study of ivermectin in TNBC remains active and is the only formal clinical trial of any drug in this stack for this specific subtype.

Glioblastoma and brain cancers benefit most from mebendazole’s blood-brain barrier crossing ability. Researchers have now documented 119 brain cancer cases in the mebendazole and ivermectin database as of March 2026 — the largest repurposed-drug brain cancer dataset in existence.

Pancreatic cancer — one of the deadliest solid tumours — shows some of the most striking individual case results, including the French patient’s 93% shrinkage after adding ivermectin and mebendazole to an otherwise unchanged chemotherapy plan.

---

Frequently Asked Questions

Can I use this full stack alongside chemotherapy or immunotherapy? Most patients in the case report database combine all four drugs with ongoing conventional treatment. Ivermectin’s multidrug resistance reversal and chemotherapy-boosting actions specifically suggest potential benefit when doctors add it alongside — rather than instead of — conventional treatment. Drug interactions, particularly HCQ’s QT effects alongside certain chemotherapy agents, need direct review with your oncologist before you start.

How long before I see a response? Case reports show responses ranging from two months to over a year. The French pancreatic cancer patient saw 93% tumour reduction within a single five-cycle chemotherapy run after adding two repurposed drugs. Other cases show gradual, sustained progress over six to twelve months. Individual tumour biology, cancer type, treatment history, and whether you run the full stack or a partial version all affect the timeline.

Do I need to start all four drugs at once? Most practitioners begin with ivermectin and one benzimidazole, watch tolerance and liver enzymes, then add compounds over the following weeks. The published Baghli-Martinez-Marik protocol starts with the triple antiparasitic combination. Doctors typically add HCQ as a fourth layer once the first three compounds are established and well tolerated. Starting all four at once without medical supervision is not a safe approach.

What is the biggest risk of this protocol? Liver enzyme rises are the most commonly reported adverse signal across all four compounds. Running a CMP every two to four weeks and adjusting doses when ALT or AST climbs meaningfully above your personal baseline catches this early, before it becomes a clinical problem. All enzyme rises in published clinical trial data reversed when doctors adjusted doses or briefly paused the drug.

How do I find a physician willing to supervise this protocol in the USA? Integrative oncology services at major cancer centres, functional medicine telehealth platforms, and the growing network of doctors aligned with drug repurposing research are all real options. Telehealth removes the geographic barrier entirely — a patient anywhere in the country can consult a licensed integrative medicine physician regardless of their home state.

---

Disclaimer: This article is for informational purposes only. Ivermectin carries FDA approval for specific parasitic infections. Mebendazole carries FDA approval for specific parasitic infections. HCQ carries FDA approval for malaria, lupus, and rheumatoid arthritis. The FDA has not approved fenbendazole for human use in the USA. No FDA approval exists for any of these drugs in cancer treatment. This guide does not constitute medical advice. Always consult a qualified oncologist or healthcare professional before adding any off-label medication to your cancer care plan.